The main objectives of this study are to determine the effect of elenestinib on the pharmacokinetic parameters (how the drug is absorbed, distributed, and processed by the body) of midazolam, and to determine the effect of elenestinib on the pharmacokinetic parameters of levonorgestrel/ethinyl estradiol, when given as a combined oral contraceptive. Healthy adult participants will receive midazolam and levonorgestrel/ethinyl estradiol with and without elenestinib and have blood samples taken.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Area under the concentration-time curve, from time 0 to the last observed non-zero concentration (AUC0-t)
Timeframe: Up to 27 days
Area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-inf)
Timeframe: Up to 27 days
Percent of AUC0-inf extrapolated (AUC%extrap)
Timeframe: Up to 27 days
Maximum observed concentration (Cmax)
Timeframe: Up to 27 days
Time to reach Cmax (Tmax)
Timeframe: Up to 27 days
Apparent first-order terminal elimination half-life (t1/2)
Timeframe: Up to 27 days
Apparent total plasma clearance after oral administration (CL/F)
Timeframe: Up to 27 days
Apparent volume of distribution during the terminal elimination phase after oral administration (Vz/F)
Timeframe: Up to 27 days